Next generation lysine gingipain inhibitor COR588 with novel structure and improved pharmacologic and safety profile prioritized for Alzheimer’s development
Additional pipeline includes therapeutics in development for coronavirus infection, periodontal disease, and prevention of oral squamous cell carcinoma
Preliminary, unaudited 2021 year-end cash, cash equivalents, and investments of $126.7 million allows for strategic flexibility
https://finance.yahoo.com/news/cortexyme-announces-pipeline-anticipated-2022-130100143.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.